These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 8823101

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of heparin-coated circuits with full heparin dose strategy.
    Sinci V, Kalaycioglu S, Gunaydin S, Imren Y, Gokgoz L, Soncul H, Ersoz A.
    Ann Thorac Cardiovasc Surg; 1999 Jun; 5(3):156-63. PubMed ID: 10413761
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA, Aeba R, Yousem SA, Griffith BP, Marrone GC.
    J Heart Lung Transplant; 1994 Jun; 13(3):498-507. PubMed ID: 8061027
    [Abstract] [Full Text] [Related]

  • 6. Clinical use of heparin-coated cardiopulmonary bypass in coronary artery bypass grafting.
    Mirow N, Minami K, Kleikamp G, Tenderich G, Puhlmann T, Körfer R.
    Thorac Cardiovasc Surg; 2001 Jun; 49(3):131-6. PubMed ID: 11432470
    [Abstract] [Full Text] [Related]

  • 7. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M, Demircin M, Guvener M, Peker O, Yilmaz M.
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S, Farsak B, McCusker K, Vijay V, Sari T, Onur MA, Gurpinar A, Zorlutuna Y.
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F, Scolletta S, Tucci E, Lucidi M, Davoli G, Toscano T, Neri E, Muzzi L, Frati G.
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [Abstract] [Full Text] [Related]

  • 13. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial.
    Alvarez JM, Jackson LR, Chatwin C, Smolich JJ.
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):457-63. PubMed ID: 11547294
    [Abstract] [Full Text] [Related]

  • 14. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
    Kutay V, Noyan T, Ozcan S, Melek Y, Ekim H, Yakut C.
    J Card Surg; 2006 Sep; 21(6):572-7. PubMed ID: 17073955
    [Abstract] [Full Text] [Related]

  • 15. Coronary artery bypass surgery with heparin-coated perfusion circuits and low-dose heparinization.
    Mullen JC, Bentley MJ, Gelfand ET, Koshal A, Modry DL, Guenther CR, Etches WS, Stang LJ, Lopushinsky SR.
    Can J Surg; 2002 Jun; 45(3):166-72. PubMed ID: 12067167
    [Abstract] [Full Text] [Related]

  • 16. Use of heparin-coated cardiopulmonary bypass circuit with low-dose heparin reduces postoperative bleeding.
    Suehiro S, Shibata T, Sasaki Y, Hattori K, Kumano H, Hosono M, Kinoshita H.
    Ann Thorac Cardiovasc Surg; 1999 Aug; 5(4):225-9. PubMed ID: 10508946
    [Abstract] [Full Text] [Related]

  • 17. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [Abstract] [Full Text] [Related]

  • 18. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery.
    Ovrum E, Tangen G, Oystese R, Ringdal MA, Istad R.
    J Card Surg; 2003 Nov; 18(2):140-6. PubMed ID: 12757341
    [Abstract] [Full Text] [Related]

  • 19. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
    Ovrum E, Holen EA, Tangen G, Brosstad F, Abdelnoor M, Ringdal MA, Oystese R, Istad R.
    Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
    [Abstract] [Full Text] [Related]

  • 20. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD, McCarthy PM, Kottke-Marchant K, Harasaki H, Pierre-Yared J, Borsh JA, Ogella DA, Cosgrove DM.
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.